Oral Prostacyclins/Analogs for PAH: Current Status and Challenges

Rubin, Lewis
June 2012
Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p7
Academic Journal
The article discusses the current status and challenges of prostacyclin therapy to pulmonary hypertension (PH) patients. It claims that different studies have been conducted whose goal is to explore the effectiveness of three main prostanoids including treprostinil, beraprost and selexipag. It indicates that patients with PH have been treated with prostanoids intravenously and subcutaneously. However, it notes that effective dosing and pharmacokinetics are yet to be further studied in the future.


Related Articles

  • Prostacyclins in Pulmonary Hypertension: The Need for Earlier Therapy. Vachiéry, Jean-Luc // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p8 

    The article examines clinical trials of prostacyclins in patients with pulmonary arterial hypertension (PAH). It mentions a diagnostic algorithm from the European Society of Cardiology and the European Respiratory Society which suggests the effectiveness of prostacyclin therapies for PAH...

  • BROMELAIN: AN ANTI-INFLAMMATORY AGENT. Seligman, Bert // Angiology;Nov1962, Vol. 13 Issue 11, p508 

    Discusses the pharmacological characteristics of bromelain. Functions of bromelain; Arterial diseases that can be manage with bromelain; Indications of bromelain.

  • The molecular targets of approved treatments for pulmonary arterial hypertension. Humbert, Marc; Ghofrani, Hossein-Ardeschir // Thorax;Jan2016, Vol. 71 Issue 1, p73 

    Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)--prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an...

  • Role of prostacyclin in pulmonary hypertension. Mitchell, Jane A.; Ahmetaj-Shala, Blerina; Kirkby, Nicholas S.; Wright, William R.; Mackenzie, Louise S.; Reed, Daniel M.; Mohamed, Nura // Global Cardiology Science & Practice;2014, Vol. 2014 Issue 4, p214 

    Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension....

  • Pulmonary Vascular Versus Right Ventricular Function Changes During Targeted Therapies of Pulmonary Hypertension. Vonk-Noordegraaf, Anton // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p20 

    The article focuses on a study which looks into the relationship between pulmonary vascular resistance (PVR) and right ventricular ejection fraction (RVEF) in patients with pulmonary hypertension (PH). The study has discovered changes in the right ventricular function and hypertensive pulmonary...

  • Current Management of Primary Pulmonary Hypertension. de Backer, T.L.M.; Smedema, J-P.; Carlier, S.G. // BioDrugs;2001, Vol. 15 Issue 12, p801 

    Primary pulmonary hypertension (PPH) is a rare disorder of the lung vasculature characterised by an increase in pulmonary artery pressure. Although the aetiology of this disease remains unknown, knowledge of the pathophysiology of the disease has advanced considerably. Diagnosis of PPH is...

  • Effect of Sepimostat Mesilate on the Development of Glomerulonephritis in NZB/W F1 Mice. Watanabe, Hiroshi; Sato, Shuzo; Saito, Rie; Iwadate, Haruyo; Kobayashi, Hiroko; and Hiromasa Ohira // Open Immunology Journal;2011, Vol. 4, p11 

    Objective: To determine whether sepimostat mesilate inhibits activation of the complement pathways, and to evaluate the effectiveness of sepimostat mesilate on the development of glomerulonephritis in NZB/W F1 mice. Methods: We used the Wielisa complement functional kit to assess the inhibitory...

  • Developing treatments for pulmonary arterial hypertension. Wilkins, Martin R. // Pulmonary Circulation;Jan-Mar2013, Vol. 3 Issue 1, p156 

    Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for...

  • Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents. Yamamoto, Koji; Takeda, Yutaka; Takeda, Yasuko; Naniwa, Taio; Narita, Hitomi; Ohte, Nobuyuki // BMC Research Notes;2014, Vol. 7 Issue 1, p2 

    Background Intravenous epoprostenol is the only drug proved in a randomized study to reduce mortality in patients with idiopathic pulmonary arterial hypertension (PAH). However, administration of this drug has procedural difficulties and a risk of sepsis. Oral drugs provide simple treatment, but...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics